Luca Rastelli

Biography

Dr. Luca Rastelli has more than 20 years of drug discovery and development experience in pharmaceutical, biotech and start-up companies. He discovered the target and led the initial development of CR011, an antibody drug conjugate agent undergoing a registrational trial in triple negative metastatic breast cancer. He has significant experience in identifying, evaluating and acquiring external innovation opportunities through collaborative and in-licensing efforts. He received the American Brain Tumor Association’s 25th Anniversary Translational grant for his work on Medulloblastoma tumors at the Department of Neuro-Oncology, MD Anderson Cancer Center. 

Research Interest

  identifying, evaluating and acquiring external innovation opportunities  metastatic breast cancer.